Everbright Securities: Maintains "Buy" rating on Consun Pharmaceutical (01681.HK), strong growth in renal business

Zhitong Finance APP has learned that Everbright Securities issued a research report stating that Consun Pharmaceutical Group (01681.HK) is a leading traditional Chinese medicine company in the nephrology sector, with steady growth and diversified advancement, and possesses attributes of high dividend yield and low valuation. The bank maintains its forecast for the company's net profit attributable to shareholders for 26-28 at RMB 1.25/1.41/1.61 billion, representing year-on-year growth of 15.5%/13.4%/13.8%, and the current stock price corresponds to PE ratios of 8.3/7.3/6.5 times. Maintain the "Buy" rating.